Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rsv-f protein nanoparticle vaccine
- Development stage
- Phase 2
- Lead developer
- Novavax
- Modality
- Nanoparticles → Drug Delivery Systems, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A **recombinant nanoparticle vaccine** composed of the respiratory syncytial virus (RSV) fusion (F) glycoprotein, engineered as nanoparticles. The F protein mediates fusion of RSV with host cells, and the vaccine aims to induce strong antibody responses, especially targeting neutralizing sites such as antigenic site II. The vaccine is being developed primarily for **maternal immunization** to prevent RSV infections in infants by transferring RSV-specific antibodies, as well as for older adults. In clinical studies, the vaccine has shown to be safe, immunogenic, and resulted in reduced evidence of RSV infection rates in vaccinated subjects compared to placebo[6]. Several formulations (with or without adjuvants, single-dose and two-dose regimens) have been tested. Developer: Novavax[2][6] Primary indication: **Prevention of RSV infection** and RSV-associated lower respiratory tract disease in infants (via maternal immunization) and older adults.
- Brand names
- ResVax
- Other names
- RSV F vaccinerecombinant RSV fusion protein nanoparticle vaccine
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on rsv-f protein nanoparticle vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rsv-f protein nanoparticle vaccine.